[en] The in vitro inhibitory effect of SR 27417, an antagonist of the platelet-activating factor (PAF) receptor, on PAF-induced platelet aggregation was studied in blood collected from seven healthy Friesien calves. Inhibitory effects of SR 27417 were determined at thirteen different concentrations (0.1-400 nM) by using the dose-response curves of PAF on calf platelet aggregation. In the presence of SR 27417, the maximal slopes of aggregation (%/min) induced by low and high concentrations of PAF were significantly different from the control values obtained without an antagonist at p < or = 0.05 and p < or = 0.01 respectively. In vitro PAF-induced calf platelet aggregation was dose-dependently inhibited by SR 27417. The drug inhibited PAF-induced platelet aggregation in a competitive reversible manner (pA2 = 10.46 +/- 2.36 mol x L(-1)). In conclusion, the results of our study showed that addition of SR 27417 to bovine platelet in vitro inhibits PAF-induced platelet aggregation. [fr] Effet inhibiteur in vitro du SR 27417, un puissant antagoniste du récepteur du facteur d'activation plaquettaire sur l'agrégation des plaquettes induite par le PAF chez le bovin. L'effet inhibiteur in vitro du SR 27417, un antagoniste du récepteur du facteur d'activation plaquettaire (PAF) induite par le PAF sur l'agrégation plaquettaire a été étudiée dans le sang prélevé des sept veaux sains de race Frisonne. L'effet inhibiteur du SR 27417 a été déterminé avec treize concentrations différentes (0,1 - 400 nM) en utilisant les courbes dose-effet du PAF sur l'agrégation plaquettaire des veaux. En présence du SR 27417, la pente d'agrégation maximale de la courbe ( concentrations du PAF ont été significativement différentes des valeurs de base ( et respectivement). L'agrégation des plaquettes induites par le PAF a été inhibée in vitro par le SR 27417 d'une manière dépendante de la dose. Le médicament a inhibé in vitro l'agrégation induite par le PAF des plaquettes chez le bovin de façon compétitive et réversible (pA2 = 10.46 2.36 molL-1). En conclusion, les résultats de notre étude montrent in vitro que l'addition du SR 27417 aux plaquettes chez le bovin inhibe l'agrégation plaquettaire induite par le PAF.
Disciplines :
Veterinary medicine & animal health
Author, co-author :
Bastos da Silva, Miriam
Delaunois, Annie ; Université de Liège - ULiège > Faculté de Médecine Vétérinaire > Laboratoire de Pharmacologie et toxicologie
Gustin, Pascal ; Université de Liège - ULiège > Faculté de Médecine Vétérinaire > Laboratoire de Pharmacologie et Toxicologie
Godeau, Jean-Marie ; Université de Liège - ULiège > Faculté de Médecine Vétérinaire > Laboratoire de Biologie Clinique
Lekeux, Pierre ; Université de Liège - ULiège > Département de sciences fonctionnelles > Physiologie
Language :
English
Title :
In Vitro Inhibitory Effect of SR 27417, a Potent Platelet-Activating Factor (PAF) Receptor Antagonist, on the PAF-Induced Bovine Platelet Aggregation
Argiolas, L., Fabi, F., Del Basso, P., Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: Role of platelets and cyclo-oxygenase metabolites (1995) Br. J. Pharmacol., 114, pp. 203-209
Bastos da Silva, M., Herion, F., Raskinet, R., David, J.-L., Gustin, P., Dessy, C., Lekeux, P., Inhibition of PAF-induced platelet aggregation by WEB 2086 in vitro, an antagonist to the receptor for platelet-activating factor, in bovine (1996) J. Vet. Med. A, 43, pp. 399-413
Bastos da Silva, M., Gustin, P., Herion, F., Raskinet, R., David, J.-L., Gougnard, T., Plomteux, G., Lekeux, P., The effect of intravenous administration of WEB 2086 on PAF-induced platelet aggregation in health Friesian calves (1997) Vet. Res. Commun., 21, pp. 521-531
Bastos da Silva, M., Dessy, C., David, J.-L., Lekeux, P., Morphological alterations of blood platelets induced by platelet activating factor (PAF) and partial inhibition by ketiprofen in calves (1997) Vet. Res., 28, pp. 489-502
Bastos da Silva, M., Gustin, P., Herion, F., David, J.-L., Van De Weerdt, M.L., Lekeux, P., Effect of ketoprofen on PAF-induced bovine platelet aggregation (1998) Vet. J., 155, pp. 201-203
Bernart, A., Herbert, J.-M., Salel, V., Lespy, L., Maffrand, J.P., Protective effect of SR 27417, a novel PAF antagonist, on PAF or endotoxin-induced hypotension in the rat and the guinea-pig (1992) J. Lipid. Mediators, 51, pp. 41-48
Bernart, A., Herbert, J.-M., Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: Importance of PAF (1994) Thromb. Res., 75, pp. 91-97
Bondy, G.S., Gentry, P.A., Characterization of the normal bovine platelet aggregation response (1989) Comp. Biochem. Physiol., C92, pp. 67-72
Born, G.V.R., Quantitative investigations into the aggregation of blood platelets (1962) J. Physiol. (Lond.), 162, p. 67
Braquet, P., Godfroid, J.J., PAF-acether binding sites: 2 designers of specific antagonists (1986) Trends Pharmacol. Sci., 7, pp. 397-403
Braquet, P., Touqui, L., Shen, T.Y., Vargaftig, B.B., Perspectives in platelet-activating factor research (1987) Pharmacol. Rev., 39, pp. 97-145
Casals-Stenzel, J., Weber, K.H., Triazolodiazepines: Dissociation of their PAF (platelet-activating factor) antagonistc and CNS activity (1987) Br. J. Pharmacol., 90, pp. 139-146
Chan, W.P., Levy, J.V., Effects of antiplatelet agents on platelet aggregation induced by platelet-activating factor (PAF) in human whole blood (1991) Prostaglandins, 42, pp. 337-342
Chcryk, L.A., Hooper-McGrevy, H.E., Gentry, P.A., Alterations in bovine platelet function and acute phase proteins induced by Patsteurella haemolytica A1 (1998) Can. J. Vet. Res., 62, pp. 1-8
Chignard, M., Le Couedic, J.P., Tencé, M., Vargaftig, B.B., Benveniste, J., The role of platelet-activating factor in platelet aggregation (1979) Nature (London), 279, pp. 799-800
Collins, L.C., Roberts, A.M., Effects of platelet-activating factor on arteriolar and venular tone in rat trachea (1997) Microvasc. Res., 53, pp. 63-72
Foster, A.P., Cunningham, F.M., Andrews, M.J., Lees, P., A comparison of the action of platelet-activating factor (PAF) antagonists WEB 2170 and 2086 in the horse (1993) J. Vet. Pharmacol. Ther., 16, pp. 477-487
Handley, D.A., Development and therapeutic indications for PAF receptor antagonist (1988) Drugs Future, 13, pp. 137-152
Heath, M.F., Evans, R.J., Hayes, L.J., Dextran-70 inhibits equine platelet aggregation induced by PAF but not by other agonists (1998) Equine Vet. J., 30, pp. 408-411
Hellewell, P.G., Williams, T.J., Antagonism of PAF-induced oedema formation in rabbit skin: A comparison of different agonists (1989) Br. J. Pharmacol., 97, p. 171
Herbert, J.M., Bernart, A., Valette, G., Gigo, V., Lale, A., Laplace, M.C., Lespy, L., Le Fur, G., Biochemical and pharmacological activities of SR 27417, a highly potent, long acting platelet activating factor receptor antagonist (1991) J. Pharmacol. Exp. Therapy, 259, pp. 44-51
Herbert, J.M., Valette, G., Bernart, A., Savi, P., Maffrand, J.P., Le Fur, G., SR 27417, a highly potent, selective and long-acting antagonist of the PAF receptor (1992) Drugs Future, 17, pp. 1011-1018
Herbert, J.M., Laplace, M.C., Maffrand, J.P., Bindind of [_H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes (1993) Biochem. Pharmacol., 45, pp. 51-58
Herbert, J.M., Bernart, A., Tibirica, E., Effect of SR 27417, a novel PAF antagonist on antigen-induced hypotension in the rat (1997) J. Lip. Mediators Cell Signal., 15, pp. 115-123
Imai, T., Adachi, M., Horikoshi, S., Sugeta, A., Idaira, K., Takahashi, T., Tanaka, Y., Relation of platelet activating factor induced airway hyperresponsiveness to thromboxane A2 and neutrophil in dogs (1993) Arerugi, 42, pp. 1563-1568
Kenakin, T.P., (1987) Pharmacological Analysis of Drug Receptor Interaction, pp. 210-217. , Raven, New York
Lekeux, P., Gustin, P., Desmecht, D., Linden, A., Thérapeutique des pathologies respiratoires aiguës des bovins (1991) Ann. Méd. Vét., 135, pp. 175-184
Leroy, P., Farnir, F., (1998) Méthodes Statistiques en Médecine Vétérinaire, pp. 251-257. , Départment de Génétique, Faculté de Médecine Vétérinaire-Université de Liége, Belgique
Livio, M., Vigano, G., Morigi, M., Ubiali, A., Galbusera, M., Remuzzi, G., Rôle of platelet-activating factor in primary hemostasis (1988) Am. J. Physiol., 254, pp. 1218-1223
Oyekan, A.O., Ablordeppey, S.Y., The mechanisms of the antiaggregatory effects of cryptolepine: The role of cyclic adenosine monophosphate and cellular Ca2+ (1993) Genet. Pharmacol., 24, pp. 461-469
Prescott, S.M., Stafforini, D.M., Zimmerman, G.A., McIntyre, T.M., The natural history of PAF: From physiological regulator to pathological mediator (1995) Proceedings 5th International Congress on Platelet-activating Factor and Related Lipid Mediators, p. 2. , Berlin
Sagara, H., Makino, S., Fukuda, T., PAF receptor antagonist in asthma therapy (1996) Nippon Rinsho, 54, pp. 3056-3061
Schorderet, M., (1988) Pharmacologie des Concepts Fondamentaux aux Applications Thérapeutiques, pp. 3-19. , Frison-Roché, Paris, Ed. Slaktine
Schumachcr, W.A., Steinbacher, T.E., Heran, C.L., Megill, J.R., Durham, S.K., Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis (1993) Thromb. Haem., 69, pp. 509-514
Soloviev, A.I., Braquet, P., Platelet-activating factor - A potent endogenous mediator responsible for coronary vasospasm (1992) News Physiol. Sci. (NIPS), 7, pp. 166-172
Terashita, Z.I., Imura, Y., Nishikawa, K., Inhibition by CV-3988 of the binding of [_H]-platelet activating factor (PAF) to the platelets (1985) Biochem. Pharmacol., 34, pp. 1491-1495
Van de Weerdt, M.-L., Desmecht, D., Lekeux, P., Effect of platelet-activating factor on bovine pulmonary function (1997) Vet. Rec., 16, pp. 168-172
Vargaftig, B.B., PAF a mediator in search of a disease (1994) Clin Rev. Allergy, 12, pp. 419-421
